AbbVie (ABBV) Stock Forecast & Price Target

Compare

22,871 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

14 Buy

5 Hold

0 Sell

Based on 19 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$218.88

▲(6.94% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $218.88 with a high forecast of $255.00 and a low forecast of $170.00. The average price target represents a 6.94% change from the last price of $204.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"169":"$169","256":"$256","190.75":"$190.8","212.5":"$212.5","234.25":"$234.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$255.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":218.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$218.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[169,190.75,212.5,234.25,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195.22,199.81846153846155,204.41692307692307,209.01538461538462,213.61384615384617,218.2123076923077,222.81076923076924,227.40923076923076,232.0076923076923,236.60615384615386,241.20461538461538,245.80307692307693,250.40153846153845,{"y":255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195.22,197.04,198.85999999999999,200.68,202.5,204.32,206.14,207.96,209.78,211.6,213.42,215.24,217.06,{"y":218.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195.22,193.28,191.34,189.4,187.46,185.52,183.57999999999998,181.64,179.7,177.76,175.82,173.88,171.94,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":183.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.16,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.9,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$255.00

Average Price Target$218.88

Lowest Price Target$170.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Carter Gould

Cantor Fitzgerald

$210→$215

Buy

5.04%

Upside

Reiterated

08/13/25

AbbVie (ABBV) Receives a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $215.00 (from $210.00) while maintaining a Overweight rating.

David Amsellem

Piper Sandler

$231

Buy

12.86%

Upside

Initiated

08/12/25

AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments

Narumi Nakagiri

Daiwa

$214

Buy

4.55%

Upside

Upgraded

08/07/25

AbbVie upgraded to Outperform from Neutral at DaiwaAbbVie upgraded to Outperform from Neutral at Daiwa

Evan Seigerman

BMO Capital

$215

Buy

5.04%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM) and GE Healthcare Technologies Inc (NASDAQ: GEHC)

Courtney Breen

Bernstein

$203

Hold

-0.82%

Downside

Reiterated

08/04/25

AbbVie: Balancing Strong Earnings with Humira Challenges and External RisksWe had gone into this print with the view that it was getting harder for to keep beating consensus on a quarterly basis. We were wrong on this for Skyrizi - which beat consensus number by 8.9% in the quarter, whilst Rinvoq beat by 2.1%. These results were uniformly approved of by investors, with stock up +3-5% until Drug pricing letters landed (QT here).

David Risinger

Leerink Partners

$210

Buy

2.60%

Upside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)

Gavin Clark-Gartner

Evercore ISI

$205→$207

Buy

1.13%

Upside

Reiterated

08/01/25

AbbVie price target raised to $207 from $205 at Evercore ISIAbbVie price target raised to $207 from $205 at Evercore ISI

Tim Anderson

Bank of America Securities

$220

Hold

7.48%

Upside

Reiterated

08/01/25

AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns

Geoff Meacham

Citi

―

Hold

―

Reiterated

08/01/25

Citi Reaffirms Their Hold Rating on AbbVie (ABBV)

Veda Pharmyne

TR | OpenAI - 4o

$208→$211

Buy

3.09%

Upside

Upgraded

08/01/25

AI Generated ArticleAI Generated Article

Asad Haider

Goldman Sachs

$197→$217

Hold

6.02%

Upside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)

Gary Nachman

Raymond James

$227→$236

Buy

15.30%

Upside

Reiterated

08/01/25

AbbVie price target raised to $236 from $227 at Raymond JamesAbbVie price target raised to $236 from $227 at Raymond James

Vamil Divan

Guggenheim

$216→$227

Buy

10.90%

Upside

Reiterated

07/31/25

Guggenheim Remains a Buy on AbbVie (ABBV)

Steve Scala

TD Cowen

$250

Buy

22.14%

Upside

Reiterated

07/31/25

TD Cowen Sticks to Its Buy Rating for AbbVie (ABBV)

Mohit Bansal

Wells Fargo

$210→$240

Buy

17.26%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Bio-Rad Laboratories (NYSE: BIO)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Carter Gould

Cantor Fitzgerald

$210→$215

Buy

5.04%

Upside

Reiterated

08/13/25

David Amsellem

Piper Sandler

$231

Buy

12.86%

Upside

Initiated

08/12/25

AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments

Narumi Nakagiri

Daiwa

$214

Buy

4.55%

Upside

Upgraded

08/07/25

AbbVie upgraded to Outperform from Neutral at DaiwaAbbVie upgraded to Outperform from Neutral at Daiwa

Evan Seigerman

BMO Capital

$215

Buy

5.04%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM) and GE Healthcare Technologies Inc (NASDAQ: GEHC)

Courtney Breen

Bernstein

$203

Hold

-0.82%

Downside

Reiterated

08/04/25

David Risinger

Leerink Partners

$210

Buy

2.60%

Upside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)

Gavin Clark-Gartner

Evercore ISI

$205→$207

Buy

1.13%

Upside

Reiterated

08/01/25

AbbVie price target raised to $207 from $205 at Evercore ISIAbbVie price target raised to $207 from $205 at Evercore ISI

Tim Anderson

Bank of America Securities

$220

Hold

7.48%

Upside

Reiterated

08/01/25

AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns

Geoff Meacham

Citi

―

Hold

―

Reiterated

08/01/25

Citi Reaffirms Their Hold Rating on AbbVie (ABBV)

Veda Pharmyne

TR | OpenAI - 4o

$208→$211

Buy

3.09%

Upside

Upgraded

08/01/25

AI Generated ArticleAI Generated Article

Asad Haider

Goldman Sachs

$197→$217

Hold

6.02%

Upside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)

Gary Nachman

Raymond James

$227→$236

Buy

15.30%

Upside

Reiterated

08/01/25

AbbVie price target raised to $236 from $227 at Raymond JamesAbbVie price target raised to $236 from $227 at Raymond James

Vamil Divan

Guggenheim

$216→$227

Buy

10.90%

Upside

Reiterated

07/31/25

Guggenheim Remains a Buy on AbbVie (ABBV)

Steve Scala

TD Cowen

$250

Buy

22.14%

Upside

Reiterated

07/31/25

TD Cowen Sticks to Its Buy Rating for AbbVie (ABBV)

Mohit Bansal

Wells Fargo

$210→$240

Buy

17.26%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Bio-Rad Laboratories (NYSE: BIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

18/28 ratings generated profit

Average Return

+3.33%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +3.33% per trade.

3 Months

xxx

Success Rate

19/25 ratings generated profit

Average Return

+7.59%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +7.59% per trade.

1 Year

Mohit BansalWells Fargo

Success Rate

21/22 ratings generated profit

Average Return

+16.20%

reiterated a buy rating 16 days ago

Copying Mohit Bansal's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +16.20% per trade.

2 Years

xxx

Success Rate

28/28 ratings generated profit

Average Return

+30.46%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 31 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 218.88.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.27 with a range of $3.11 to $3.39. The previous quarter’s EPS was $2.97. ABBV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $15.55B with a range of $15.10B to $15.98B. The previous quarter’s sales results were $15.42B. ABBV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 218.88.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 6.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 218.88. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $255.00 ,the lowest forecast is $170.00. The average price target represents 6.94% Increase from the current price of $204.68.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts